Celltrion Launches Omalizumab Biosimilar in the United States

Start
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first and only FDA-approved interchangeable biosimilar to Genentech and Novartis’s XOLAIR® (omalizumab)….
By: Goodwin
Previous Story

States Target Artificial Intelligence in Employment Decisions

Next Story

The Four Eras of Search: From “Which Keywords?” to “What Happened?”